ARPE-19 as a platform cell line for encapsulated cell-based delivery
US7115257B1 · kind B1 · utility
27Cited by
16References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 6, 2000 |
| Grant date | Oct 3, 2006 |
| Priority date | — |
| Expiry date | Apr 6, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2035/128
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
ARPE-19 cells were evaluated as a platform cell line for encapsulated and unencapsulated cell-based delivery technology. ARPE-19 cells were found to be hardy (the cell line is viable under stringent conditions, such as in central nervous system or intra-ocular environment); can be genetically modified to secrete the protein of choice; have a long life span; are of human origin; have good in vivo device viability; deliver efficacious quantity of growth factor; trigger no or low level host immune reaction, and are non-tumorigenic.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.